As per the agreement, Cellectis is responsible for supplying preselected meganucleases to VitamFero to utilize in the development of vaccines against parasites responsible for toxoplasmosis, neosporosis, and others.
Cellectis CEO Andre Choulika said they are delighted to be working with VitamFero in this field to promote the development of a new application of our technology.
VitamFero CEO Pascal Breton said this agreement represents an important step forward for their company, by getting access to Cellectis’ intellectual propriety and strengthening their technological potential in the modification of the genomes of apicomplex parasites.